At a glance

ClinicalIndex Comparison Record

Phase 3Completed· 114 enrolled

Drug / intervention

Fondaparinuxdrug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00320398

NCT00320398Phase 3Completed

Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in Prevention of Venous Thromboembolism After Elective Total Hip Replacement Surgery

GlaxoSmithKline·interventional·Posted May 3, 2006·Updated Sep 4, 2018

In Brief

A Phase 3 clinical trial evaluating Fondaparinux for Thrombosis, Venous. Completed, enrolled 114 participants across 1 site.

This study is requested by PMDA to confirm the optimal dose for THR (total hip replacement).

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

Countries--

Collaborators--

Phase 3CompletedFinished

2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Enrollment StartJan 2006

First PostedMay 2006

Primary CompletionJul 2006

TodayJul 2026

First PostedMay 3, 2006

Enrollment StartJan 30, 2006

Primary CompletionJul 18, 2006

TodayJul 2, 2026

Enrollment to primary: 6 monthsPosted 20.2 years ago

Fondaparinuxdrug